AUNA S.A. (AUNA): Financial results for Q2 2026

AUNA S.A. (AUNA) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Auna Announces 2Q26 Financial Results A consecutive quarter of strong top-line growth and cash flow performance; Consolidated Adjusted EBITDA impacted by service mix across the segments Luxembourg, August 18, 2026 – Auna (NYSE: AUNA) (“Auna” or the “Company”) , a lea

Event · Earnings
Also in this documentGuidance · reaffirm · 10%–14%

Facts are quoted from the filing text and checked against it.

Original reporting
Published Aug 18, 2026, 9:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 28, 2026, 6:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$AUNA
Neutral
high confidence
Mentioned
$AUNA
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 6-K
Decision brief

The 30-second read

$AUNANeutralMed
01

Why it matters

The earnings release provides fresh financial metrics and expansion updates that can influence stock valuation.

02

Market read

First report of Q2 2026 earnings for AUNA, offering actionable data for traders.

03

What to watch

Potential regulatory changes in Peru and Colombia and currency fluctuations may affect future results.

Relevance 7/10Novelty 7/10Timing: post‑earnings release Aug 18 2026

Background

Auna is a leading Latin American healthcare platform listed on NYSE, providing hospital and oncology services.

Company-level read

Ticker impact

$AUNANeutralHigh confidence
Context

Auna reported Q2 2026 results with revenue up 9% YoY and adjusted EBITDA down 9% YoY, plus guidance and operational updates.

Expected impact

Potential short-term volatility as investors digest mixed earnings; upside if guidance holds, downside if margin concerns dominate.

Evidence & confidence

First disclosure of earnings with detailed numbers and operational outlook provides clear trading signals.

Market effects

Highlights growth and margin dynamics in Latin American healthcare sector.

Positive for regional markets in Mexico, Peru, Colombia as healthcare demand rises.

Limited to investors focused on emerging‑market healthcare exposure.

Counterpoint

Margin compression and service mix risks could outweigh revenue growth, suggesting a short bias.

Key entities

  • Abraham Galán

    New Chief Technology Officer appointed Aug 3 2026.

Related articles

$AUNAMed

Auna S.A. (AUNA) Stock Falls on Q3 2026 Earnings

Auna S.A. (AUNA) reported Q3 2026 revenue of $384.7M, up 19.4% YoY, with net income falling 57.4% to $5.9M. Operating cash flow rose 38.9% to $77.6M. Insiders made 6 purchases and 1 sale in the past 6 months. Hedge funds showed mixed activity, with some increasing and others decreasing positions.

$AUNAMed

AUNA S.A. (AUNA): Financial results for Q3 2026

AUNA S.A. (AUNA) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Auna Announces 3Q26 Financial Results Auna reports 10% FX-Neutral Revenue Growth and Continued Strong Cash Generation in 3Q2026; Mexico Returns to Year-over-Year Adjusted EBITDA Growth; Profitability Pressured by Specific Headwinds in Colombia and Peru Leverage Impro

$AUNAHigh

Why is Auna stock dropping today?

Auna SAA ADR stock fell 9.2% to $4.91 after revising its 2026 profitability outlook, citing higher cancer diagnosis costs in Colombia. The company maintained its revenue growth target but saw a sell-off amid broader market declines. The stock dropped to a session low of $4.55, nearing its 52-week low of $4.09.

$AUNAMed

Auna (AUNA) Q2 2026 Earnings Call Transcript

Auna (AUNA) reported Q2 2026 results with 9% revenue growth driven by volume and higher complexity services. Adjusted EBITDA declined 9% due to margin pressures in Mexico and Colombia, and billing penalties in Peru. Mexico saw 7% surgery and 20% oncology volume growth, while Peru achieved 8% revenue growth. Colombia's adjusted EBITDA increased 18% sequentially. Leverage decreased to 3.6x, and cash increased 43% year-over-year.